Abstract Number: 1294 • ACR Convergence 2025
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…Abstract Number: 1232 • ACR Convergence 2025
Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Background/Purpose: Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that it might improve health related bodily…Abstract Number: 1044 • ACR Convergence 2025
Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Background/Purpose: Hydroxychloroquine is a cornerstone in the treatment of Systemic Lupus Erythematosus (SLE), while corticosteroids and immunosuppressive agents are employed for moderate to severe disease…Abstract Number: 0937 • ACR Convergence 2025
MRL-lpr Mice Display Altered Nociception: A new model for lupus peripheral neuropathy
Background/Purpose: Of the 19 ACR case definitions for NPSLE, seven involve the peripheral nervous system. MRL/lpr mice spontaneously develop anti-dsDNA antibodies, nephritis, and skin disease,…Abstract Number: 0667 • ACR Convergence 2025
Retrospective Chart Audit Reveals Gaps in Steroid Tapering and Use of ACR Guideline-Recommended Regimens in LN
Background/Purpose: In May 2025, ACR released updated recommendations for the management of LN2. Notably, since the previous guidelines update in 2012, the FDA has approved…Abstract Number: 0644 • ACR Convergence 2025
Improvement of Fatigue, Musculoskeletal Pain, and Morning Stiffness in Patients with Systemic Lupus Erythematosus Treated with Dapirolizumab Pegol: 48-Week Results from a Phase 3 Trial
Background/Purpose: Fatigue, musculoskeletal pain, and joint stiffness are common manifestations of SLE, presenting considerable treatment challenges, particularly in addressing chronic fatigue. Dapirolizumab pegol (DZP) is…Abstract Number: 0623 • ACR Convergence 2025
Cluster Analysis of Socioeconomic and Environmental Determinants Modifying Activity, Chronicity and Clinical Manifestations of Systemic Lupus Erythematosus in the GLADEL 2.0 Cohort
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Evidence from high-income countries suggests that socioeconomic status (SES) and environmental…Abstract Number: 0607 • ACR Convergence 2025
Age at Diagnosis of SLE has Increased in a United States Longitudinal Cohort
Background/Purpose: The demographics of our lupus cohort have shifted over the decades towards an older population. While much of the shift can be attributed to…Abstract Number: 0851 • ACR Convergence 2025
Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
Background/Purpose: Kidney survival is the ultimate treatment goal in lupus nephritis (LN), but long-term predictors remain understudied due to the need for extensive follow up.…Abstract Number: 0772 • ACR Convergence 2025
Redefining When to Biopsy the Kidney in Patients with SLE
Background/Purpose: Current ACR, EULAR and KDIGO guidelines recommend kidney biopsy in SLE patients with urine protein to creatinine (UPCR) ratio of >= 0.50 g/g. However,…Abstract Number: 0188 • ACR Convergence 2025
Investigating Canadians’ information needs related to lupus: A Google Trends analysis of online search query data
Background/Purpose: A lack of knowledge surrounding SLE has been identified as a main challenge for patients, particularly those seeking a diagnosis or recently diagnosed. Subsequently,…Abstract Number: 1508 • ACR Convergence 2025
Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by systemic inflammation, autoantibody production, and multiorgan involvement. Although genetic, hormonal, and environmental factors…Abstract Number: 2664 • ACR Convergence 2025
Neutrophil-to-Lymphocyte Ratio (NLR) as a Clinically Accessible Marker for Interferon Signatures in Autoimmune Diseases
Background/Purpose: Interferons (IFNs) play critical roles in systemic autoimmune diseases, particularly systemic lupus erythematosus (SLE), where heightened type I IFN signaling is a hallmark. Elevated…Abstract Number: 2580 • ACR Convergence 2025
Estrogen Modulates Neutrophil Biology: Implications for Autoimmunity
Background/Purpose: Neutrophils are essential for inflammation and host defense against infections. Our group has previously highlighted their key roles in the pathogenesis of diseases that…Abstract Number: 2463 • ACR Convergence 2025
Allogenic anti- CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with significant morbidity and mortality. The treatment approach for SLE primarily involves immunomodulation and…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 181
- Next Page »
